FILE:DGX/DGX-8K-20080722074102.txt.gz
EVENTS:	Results of Operations and Financial Condition	Financial Statements and Exhibits
TEXT:
ITEM: Results of Operations and Financial Condition
ITEM: Financial Statements and Exhibits
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
Item 2.02. Results of Operations and Financial Condition
On July 22, 2008, Quest Diagnostics Incorporated issued a press release announcing, among other things, its results for the quarter ended June 30, 2008. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
 
Item 9.01. Financial Statements and Exhibits
 
 
 
          
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 

Exhibit 99.1
Total revenues of $1.8 billion, up 12%;
Diluted earnings of $0.83 per share, up 14%;
Cash flow improved to $213 million;
2008 EPS guidance midpoint increased, new range $3.10 to $3.20 per diluted share.
MADISON, N.J., JULY 22, 2008Quest Diagnostics Incorporated (NYSE: DGX), the worlds leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2008, income from continuing operations rose to $162 million, or $0.83 per diluted share, from $142 million, or $0.73 per diluted share, in the second quarter of 2007.
Second quarter revenues increased 12% to $1.8 billion. The inclusion of AmeriPath, which the company acquired on May 31, 2007, increased consolidated revenues by 8.1% . Clinical testing revenues increased by 12.4% compared to the prior year. Revenue per requisition increased 7.1% and clinical testing volume, measured by the number of requisitions, increased 4.9% . The acquisition of AmeriPath increased revenue per requisition by 4.5% and clinical testing volume by 3.9% ..
We delivered another strong quarter, and I am pleased with our performance, said Surya N. Mohapatra, Ph.D., Chairman and Chief Executive Officer. We differentiate ourselves and drive profitable growth by providing a superior experience for patients, physicians and hospitals. This focus enabled us to grow revenues by 12% and improve operating margin to 16.8% . In addition, we made solid progress toward reaching our $500 million cost reduction objective.
For the second quarter, operating income increased to $308 million, or 16.8% of revenues, from $272 million, or 16.6% of revenues in 2007. Bad debt expense as a percentage of revenues was 4.4%, compared to 4.3% at the end of the second quarter of 2007. Days sales outstanding improved to 46 days, compared to 48 days at the end of the first quarter of 2008 and 51 days a year ago. Cash flow from operations increased to $213 million from $129 million in the second quarter of 2007. During the quarter, the company reduced debt by $168 million, and made capital expenditures of $48 million.
First Half Performance
For the first six months of 2008, income from continuing operations increased to $303 million, or $1.55 per diluted share, from $249 million, or $1.28 per diluted share in the first half of 2007. Revenues increased 14.4% to $3.6 billion. The acquisition of AmeriPath increased consolidated revenues by 10.5% .
Operating income for the first half of 2008 increased to $588 million, or 16.2% of revenues, compared to $473 million, or 14.9% of revenues in 2007. Cash from operations increased to $371 million from $280 million in 2007. During the first half of 2008, the company reduced debt by $281 million, and made capital expenditures of $95 million.
 
 
Outlook for 2008: Midpoint for EPS guidance increased
For the full year 2008, the company now expects results from continuing operations as follows: earnings per diluted share of between $3.10 and $3.20, compared to the previous range of $3.00 to $3.20; revenue growth of approximately 9%, and operating income to approach 17% of revenues. Over the same period, the company expects cash from operations to approximate $900 million and capital expenditures of between $240 million and $260 million. These estimates exclude potential special charges.
Quest Diagnostics will hold its second quarter conference call on July 22, 2008 at 8:30 A.M. Eastern Time. A simulcast of the call is available by dialing 210-839-8500, passcode 3214469 and via the Internet at: www.questdiagnostics.com. Registered analysts may access the call at: www.streetevents.com. In addition, a replay of the call will be available from 10:30 A.M. on July 22 through midnight on August 19, 2008 to investors in the U.S. by dialing 866-431-7950. Investors outside the U.S. may dial 203-369-0981. No password is required for either number.
About Quest Diagnostics
Quest Diagnostics is the worlds leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.
Quest Diagnostics maintains one of the largest private clinical laboratory databases in the United States. The data is used to generate Quest Diagnostics Health Trends, which identifies and tracks disease and wellness benchmarks, and the Drug Testing Index, which is published as a public service for government, media and industry and has been considered a benchmark for national drugs-of-abuse trends since its inception in 1988. Additional company information is available at
www.questdiagnostics.com
.
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in Business in Part I, Item 1, Risk Factors and Cautionary Factors that May Affect Future Results in Item I, Part 1A, Legal Proceedings in Part I, Item 3, Managements Discussion and Analysis of Financial Condition and Results of Operations in Part II, Item 7 and Quantitative and Qualitative Disclosures About Market Risk in Part II, Item 7A in the companys 2007 Annual Report on Form 10-K and Managements Discussion and Analysis of Financial Condition and Results of Operations and Quantitative and Qualitative Disclosures about Market Risk in the companys 2008 Quarterly Reports on Form 10-Q and other items throughout the Form 10-K and the companys 2008 Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
 
 
 
 
 
 
 
 
Notes to Financial Tables
1)    The computation of basic and diluted earnings per common share is as follows:
 
 
 
 
 
 
 
 
 
 
 
 
 
 


